UA41502C2 - Стабілізований фармацевтичний препарат, який містить гормон росту і гістидин, кристали гормону росту, що містять гістидин, та спосіб їх одержання - Google Patents

Стабілізований фармацевтичний препарат, який містить гормон росту і гістидин, кристали гормону росту, що містять гістидин, та спосіб їх одержання

Info

Publication number
UA41502C2
UA41502C2 UA94005308A UA94005308A UA41502C2 UA 41502 C2 UA41502 C2 UA 41502C2 UA 94005308 A UA94005308 A UA 94005308A UA 94005308 A UA94005308 A UA 94005308A UA 41502 C2 UA41502 C2 UA 41502C2
Authority
UA
Ukraine
Prior art keywords
growth
pharmaceutical preparation
hormyste
histidins
histidines
Prior art date
Application number
UA94005308A
Other languages
English (en)
Inventor
Ханс Холмегард Соренсен
Ларс Скрівер
Анні Рассінг Хоелгард
Original Assignee
Ново Нордіск А/С
Ново Нордиск А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK204691A external-priority patent/DK204691D0/da
Priority claimed from DK136492A external-priority patent/DK136492D0/da
Application filed by Ново Нордіск А/С, Ново Нордиск А/С filed Critical Ново Нордіск А/С
Publication of UA41502C2 publication Critical patent/UA41502C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Винахід стосується медицини та хіміко-фармацевтичної промисловості, зокрема створення і виробництва лікарських засобів, які використовуються в терапії дерматозів різної етіології. До складу засобу для лікування дерматозів входять такі компоненти (мас. %): фладексан (1,00-2,00), вазелін медичний (15,00-20,00), стеаринова кислота (2,00-5,00), пропіленгліколь (10,00-18,00), емульгатор №1 (5,00-8,00), ніпагін (0,06-0,07), ніпазол (0,03-0,04), вода очищена (решта). Технічний результат, який досягається в разі здійснення винаходу, полягає в комплексному впливові на уражені тканини. При цьому досягається біль широкий спектр терапевтичної дії с одночасним додержанням норм мікробного забруднення в процесі виробництва препарату, а також при його зберіганні і застосуванні.
UA94005308A 1991-12-20 1992-12-16 Стабілізований фармацевтичний препарат, який містить гормон росту і гістидин, кристали гормону росту, що містять гістидин, та спосіб їх одержання UA41502C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK204691A DK204691D0 (da) 1991-12-20 1991-12-20 Hidtil ukendt farmaceutisk praeparat
DK136492A DK136492D0 (da) 1992-11-10 1992-11-10 A pharmaceutical formulation
PCT/DK1992/000379 WO1993012812A1 (en) 1991-12-20 1992-12-16 A stabilized pharmaceutical formulation comprising growth hormone and histidine

Publications (1)

Publication Number Publication Date
UA41502C2 true UA41502C2 (uk) 2001-09-17

Family

ID=26065653

Family Applications (1)

Application Number Title Priority Date Filing Date
UA94005308A UA41502C2 (uk) 1991-12-20 1992-12-16 Стабілізований фармацевтичний препарат, який містить гормон росту і гістидин, кристали гормону росту, що містять гістидин, та спосіб їх одержання

Country Status (24)

Country Link
EP (2) EP0618807B1 (uk)
JP (2) JP2950617B2 (uk)
KR (1) KR100266502B1 (uk)
AT (2) ATE227583T1 (uk)
AU (1) AU667503B2 (uk)
BG (1) BG63075B1 (uk)
CA (1) CA2125855C (uk)
CZ (1) CZ283361B6 (uk)
DE (3) DE69232847T2 (uk)
DK (1) DK0618807T3 (uk)
ES (2) ES2185625T3 (uk)
FI (1) FI115116B (uk)
HU (1) HUT69402A (uk)
IL (1) IL104152A (uk)
MX (1) MX9207374A (uk)
NL (1) NL300126I1 (uk)
NO (1) NO942300L (uk)
NZ (1) NZ246556A (uk)
PT (1) PT618807E (uk)
RO (1) RO111990B1 (uk)
RU (1) RU2122426C1 (uk)
SK (1) SK279641B6 (uk)
UA (1) UA41502C2 (uk)
WO (1) WO1993012812A1 (uk)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US6022858A (en) * 1991-12-20 2000-02-08 Novo Nordisk A/S Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
US5849700A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US6288030B1 (en) * 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
DE69420872T2 (de) * 1994-06-17 2000-01-13 Applied Research Systems Hgh enthaltende pharmazeutische zubereitungen
IL114030A (en) * 1994-06-27 2000-08-13 Hayashibara Biochem Lab Saccharide composition with a lesser reducibility its preparation and compositions containing it
US5654278A (en) * 1994-10-13 1997-08-05 Novo Nordisk A/S Composition and method comprising growth hormone and leucine
US5547696A (en) * 1994-10-13 1996-08-20 Novo Nordisk A/S Pharmaceutical formulation
US5631225A (en) * 1994-10-13 1997-05-20 Novo Nordisk A/S Pharmaceutical formulation
IL115592A (en) * 1994-10-13 2000-07-26 Novo Nordisk As Stabilized pharmaceutical formulation comprising a growth hormone and leucine
EP0805689A1 (en) * 1995-01-13 1997-11-12 Novo Nordisk A/S A stabilized pharmaceutical formulation comprising a growth hormone and x-lys
ZA96122B (en) * 1995-01-13 1996-07-24 Novo Nordisk As A pharmaceutical formulation
US5705482A (en) * 1995-01-13 1998-01-06 Novo Nordisk A/S Pharmaceutical formulation
US5552385A (en) * 1995-06-05 1996-09-03 Novo Nordisk A/S Pharmaceutical formulation
US6936289B2 (en) 1995-06-07 2005-08-30 Danisco A/S Method of improving the properties of a flour dough, a flour dough improving composition and improved food products
ZA965367B (en) * 1995-07-12 1997-01-23 Novo Nordisk As A pharmaceutical formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
KR100236393B1 (ko) * 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
US20070179096A1 (en) 1996-04-24 2007-08-02 Novo Nordisk A/S Pharmaceutical Formulation
US20020077461A1 (en) * 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
CA2309955A1 (en) * 1997-11-12 1999-05-20 Alza Corporation Method for decreasing self-association of polypeptides
WO1999055310A1 (en) * 1998-04-27 1999-11-04 Altus Biologics Inc. Stabilized protein crystals, formulations containing them and methods of making them
KR20090007504A (ko) 2000-02-24 2009-01-16 몬산토 테크놀로지 엘엘씨 소마토트로핀의 지속적인 방출을 위한 비수성 주사제제들
US6719992B2 (en) 2000-06-26 2004-04-13 Monsanto Technology Llc Non-aqueous surfactant-containing formulations for extended release of somatotropin
US6664234B1 (en) 2000-06-30 2003-12-16 Monsanto Technology Llc Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin
JP2004515467A (ja) 2000-08-07 2004-05-27 ネクター セラピューティックス 吸入可能な、噴霧乾燥した、最少の凝集物を有する４−ヘリックスバンドルタンパク質粉末
ES2477996T3 (es) 2000-08-11 2014-07-18 Chugai Seiyaku Kabushiki Kaisha Preparaciones estabilizadas que contienen un anticuerpo
DE60220155T2 (de) 2001-05-18 2008-02-07 Danisco A/S Verfahren zur herstellung von teig mit einem enzym
AU2003300126B2 (en) * 2002-12-31 2010-04-01 Altus Pharmaceuticals Inc. Complexes of protein crystals and ionic polymers
CA2512052C (en) 2002-12-31 2016-06-21 Altus Pharmaceuticals Inc. Human growth hormone crystals and methods for preparing them
AU2004261353B2 (en) 2003-08-05 2009-12-10 Novo Nordisk A/S Novel insulin derivatives
AU2005263954B2 (en) 2004-07-16 2011-04-07 Dupont Nutrition Biosciences Aps Enzymatic oil-degumming method
WO2006065861A2 (en) * 2004-12-15 2006-06-22 Amgen Inc Therapeutic formulations of keratinocyte growth factor
BRPI0519170A8 (pt) * 2004-12-22 2018-05-08 Ambrx Inc formulações de hormônio de crescimento humano que compreendem um aminoácido não naturalmente codificado
EP1928906A2 (en) * 2005-08-30 2008-06-11 Novo Nordisk Health Care AG Liquid formulations of pegylated growth hormone
WO2007033427A1 (en) * 2005-09-23 2007-03-29 Metabolic Pharmaceuticals Limited Stabilisation of peptides with basic amino acids
ATE519780T1 (de) 2005-12-28 2011-08-15 Novo Nordisk As Ein acyliertes insulin und zink enthaltende zusammensetzungen und verfahren zur herstellung dieser zusammensetzungen
EP2040757A2 (en) 2006-07-07 2009-04-01 Novo Nordisk Health Care AG New protein conjugates and methods for their preparation
US8071544B2 (en) * 2006-12-18 2011-12-06 Althea Technologies, Inc. Crystallized recombinant human growth factor formulations
EP2167032B1 (en) 2007-06-13 2019-08-07 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
CN102202683A (zh) 2008-10-30 2011-09-28 诺沃-诺迪斯克有限公司 用少于每日一次的注射频率注射胰岛素来治疗糖尿病
BR122020010601B8 (pt) * 2008-12-16 2021-07-27 Genzyme Corp conjugados de proteína-oligossacarídeo, seus usos, e composições farmacêuticas
US9238878B2 (en) 2009-02-17 2016-01-19 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
US20120283172A1 (en) 2009-12-21 2012-11-08 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
CN107674121A (zh) 2009-12-21 2018-02-09 Ambrx 公司 经过修饰的牛促生长素多肽和其用途
AU2011306653B2 (en) * 2010-09-21 2014-06-05 Ferring B.V. Improved process for production of recombinant human growth hormone
RU2013123515A (ru) 2010-10-27 2014-12-10 Ново Нордиск А/С Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами
KR20140016262A (ko) 2011-01-14 2014-02-07 레드우드 바이오사이언스 인코포레이티드 알데하이드-태깅된 면역글로불린 폴리펩타이드 및 이의 사용 방법
CA2875446A1 (en) 2012-06-05 2013-12-12 Neuroderm Ltd. Compositions comprising apomorphine and organic acids and uses thereof
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
US11559580B1 (en) * 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
AU2015416589B2 (en) * 2015-12-10 2021-04-01 Menicon Co., Ltd. Peptide composition
WO2017189432A1 (en) 2016-04-26 2017-11-02 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
US20210188941A1 (en) * 2018-05-25 2021-06-24 Dr. Reddy's Laboratories Limited Stable fusion protein formulation
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
WO2022197963A1 (en) * 2021-03-19 2022-09-22 Pfizer Inc. Long-acting growth hormone compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
US4917685A (en) * 1986-05-16 1990-04-17 International Minerals & Chem. Corp. Delivery device for the administration of stabilized growth promoting hormones
EP0374120A3 (en) * 1988-12-13 1991-07-31 Monsanto Company Comosition for controlled release of polypeptides
DK168790D0 (uk) * 1990-07-13 1990-07-13 Novo Nordisk As

Also Published As

Publication number Publication date
CA2125855A1 (en) 1993-07-08
FI942906A0 (fi) 1994-06-17
EP1197222B1 (en) 2007-08-01
EP1197222A3 (en) 2004-02-04
SK279641B6 (sk) 1999-01-11
CZ283361B6 (cs) 1998-03-18
NZ246556A (en) 1996-03-26
DE69233704D1 (de) 2007-09-13
RU2122426C1 (ru) 1998-11-27
DE69233704T2 (de) 2008-05-21
AU667503B2 (en) 1996-03-28
JPH11315031A (ja) 1999-11-16
NO942300D0 (no) 1994-06-17
DE10399015I1 (de) 2012-05-03
IL104152A0 (en) 1993-05-13
FI942906A (fi) 1994-06-17
SK75494A3 (en) 1995-03-08
NL300126I1 (nl) 2003-07-01
ES2185625T3 (es) 2003-05-01
PT618807E (pt) 2003-03-31
JPH07502516A (ja) 1995-03-16
NO942300L (no) 1994-08-19
IL104152A (en) 1998-06-15
EP0618807B1 (en) 2002-11-13
BG63075B1 (bg) 2001-03-30
ATE368472T1 (de) 2007-08-15
HUT69402A (en) 1995-09-28
HU9401832D0 (en) 1994-09-28
DE10399015I2 (de) 2008-08-07
DK0618807T3 (da) 2003-03-03
CZ150794A3 (en) 1995-01-18
FI115116B (fi) 2005-03-15
KR100266502B1 (ko) 2000-09-15
ES2291264T3 (es) 2008-03-01
ATE227583T1 (de) 2002-11-15
JP2950617B2 (ja) 1999-09-20
MX9207374A (es) 1993-07-01
WO1993012812A1 (en) 1993-07-08
EP1197222A2 (en) 2002-04-17
RO111990B1 (ro) 1997-04-30
EP0618807A1 (en) 1994-10-12
AU3344693A (en) 1993-07-28
DE69232847D1 (de) 2002-12-19
CA2125855C (en) 2008-05-13
BG98806A (bg) 1995-02-28
RU94045932A (ru) 1997-04-20
DE69232847T2 (de) 2003-09-11

Similar Documents

Publication Publication Date Title
UA41502C2 (uk) Стабілізований фармацевтичний препарат, який містить гормон росту і гістидин, кристали гормону росту, що містять гістидин, та спосіб їх одержання
FI942905A (fi) Stabiloitu kasvuhormonia ja asparagiinia sisältävä farmaseuttinen formulointi
FI101194B1 (fi) Menetelmä stabiloidun, gonadotropiinia sisältävän lyofilisaatin valmistamiseksi
ES2173197T3 (es) Una formula farmaceutica que contiene hormona de crecimiento e isoleucina.
KR970706840A (ko) 성장호르몬 및 발린으로 이루어진 약학적 조성물(a pharmaceutical formulation comprising a growth hormone and valine)
MX9800309A (es) Formulacion farmaceutica estabilizada que comprende una hormona del crecimiento y un peptido que comprende al menos un residuo de aminoacido basico y al menos un residuo de aminoacido acido.